SOURCE: Beleave Inc.

Beleave Inc.

April 18, 2016 09:05 ET

Beleave Signs Letter of Intent With gDial Inc. Regarding Proprietary Drug Dosing, Detection, and Usage-Tracking Technology

TORONTO, ON--(Marketwired - April 18, 2016) - Beleave Inc. (CSE: BE) ("Beleave" or the "Company") is pleased to announce that it has entered into a letter of intent ("LOI") to pursue a collaborative partnership (the "Partnership") with gDial Inc. ("gDial"), whereby both parties will participate in the research, development, and licencing of a proprietary drug dosing, detection, and usage-tracking technology to be used to evaluate and report the chemical composition of vaporized medicinal marihuana plant or extract material within a clinical setting.

The technology aims to provide reproducible delivery of phytoceutical compounds that are released following vaporization of standardized marihuana products, by providing a mechanism that measures and tracks output of these compounds for precision dosing, which can be used for reporting of medicinal usage to treating physicians. The usage-tracking component of the technology will involve gDial's proprietary BioTIFF software platform, which can be used to satisfy medical oversight regulatory requirements for clinical applications.

With the widely varying and diverse chemical profiles of commercially available marihuana products, such highly characterized usage will allow particular physiological effects to be attributed to specific compounds. This will allow physicians better oversight of patients' use of medicinal marihuana products, the development of personalized and customized treatment options to optimize symptom management, as well as the potential to inform clinical research and public health policy.

"We are thrilled to partner with our friends at gDial. This technology will provide more standardized and regulated dosing, which will go a long way in correlating health and wellness outcomes associated with marihuana usage to specific phytoceutical determinants present in plant and extract material," commented Beleave CEO Dr. Roger Ferreira. "Importantly, we feel our individual company skillsets complement one another to bring a revolutionary product to market."

Beleave and gDial first plan to evaluate applications of their technology for usage with vaporization devices, along with a reputable Canadian vaporizer manufacturer. Vaporization allows a non-smoked route of administration for marihuana whereby the plant or extract material is heated to a temperature that releases medicinally relevant compounds in vapor, without the need to burn the material where harmful smoke is produced. The aim will be to obtain medical device status for a usage-tracking vaporization device, in order to allow patient users the ability to apply for insurance coverage to cover costs associated with it, making it relatively inexpensive for patient end-users. Tracking patient usage, and vaporization devices, represent two exciting and revolutionary areas of innovation in the Canadian, U.S., and global medicinal marihuana markets.

About gDial
gDial Inc. is an Ontario based start-up company developing services around accessioning, indexing, and authenticating collections of digital record based-data for health systems. gDial president, Peter Pennefather, is an associate professor at the University of Toronto, Department of Pharmaceutical Science, with cross-appointments in the departments of Physiology and Institute of Medical Science. Dr. Pennefather serves as academic director of the UofT Laboratory for Collaborative Diagnostics (LCD). His research focuses on using and sharing uninterpreted wellness-relevant raw data within health systems, and his work on drug testing technology has led to two patents. Together with Dr. West Suhanic, co-founder of the LCD and CEO of affiliated gDial Inc., they are developing the BioTIFF software platform for managing petabytes of big raw data, and an open computer web server design to host it.

About Beleave
Beleave Inc. (formerly Stream Ventures Inc.) is a biotech company committed to becoming a licensed producer under the Marihuana for Medical Purposes Regulations (the "MMPR"). Beleave's wholly owned subsidiary First Access Medical Inc. ("FAM") has applied for a licence to cultivate and sell medical marihuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario.

Forward-Looking Statements
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Corporation believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Corporation can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the MMPR licensing process and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Corporation's disclosure documents, which can be found under the Corporation's profile on www.sedar.com.

Contact Information